Yep. We need lower costs but more importantly he seems to be the sort of guy who can get us up to recovery metrics. The better he does, the lower the treatment charges.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025